Assertio Holdings 2025 Q2 Earnings Worse Losses Amid Revenue Decline

Assertio Holdings reported its fiscal 2025 Q2 earnings on August 11, 2025, showing a significant deterioration in earnings performance despite narrowing its full-year guidance, reflecting a challenging operational environment.

Revenue
The company’s total revenue declined by 6.1% year-over-year to $29.22 million in Q2 2025, with a strong showing from Rolvedon and Sympazan offset by softer performance in other product categories. Rolvedon accounted for $16.13 million in sales, while Sympazan added $3.24 million. INDOCIN products and SPRIX contributed $3.03 million and $1.98 million, respectively. Other products totaled $4.44 million, and the company also reported $400,000 in royalty revenue.

Earnings/Net Income
Assertio’s losses deepened significantly, with a net loss of $16.35 million in Q2 2025 compared to $3.67 million in the prior year, representing a 345.1% increase. On a per-share basis, the loss expanded to $0.17 from $0.04, a 325% increase in the negative direction, signaling a deteriorating earnings trend.

Price Action
The stock price edged down 2.03% during the latest trading day, but showed marginal gains of 0.67% over the past week and 2.10% month-to-date.

Post-Earnings Price Action Review
A strategy of buying Assertio’s shares on the earnings date and holding for 30 days has underperformed relative to the benchmark over the past three years, yielding a -27.69% return versus the benchmark’s 60.59%. Although the strategy showed no significant drawdowns, it exhibited high volatility (48.91%) and a negative Sharpe ratio of -0.23, indicating a relatively risky and unprofitable approach.

CEO Commentary
CEO Brendan P. O’Grady highlighted the company’s strong second-quarter execution within its transformation phase, emphasizing improved operating performance and updated guidance. He underscored robust demand for Rolvedon and Sympazan, driven by expanded provider access and increased prescriptions. O’Grady outlined five key transformation priorities, including reducing legal exposure, simplifying corporate structure, and pursuing strategic transactions. The CEO expressed confidence in the company’s pivot to a commercially focused specialty pharma model and its ability to drive long-term value.

Guidance
Assertio narrowed its 2025 net product sales guidance to a range of $108 million to $118 million and adjusted its EBITDA forecast to $11 million to $19 million. These updates reflect improved operating efficiencies, decommercialization of Otrexup, and cost management progress. CFO Ajay Patel noted that the EBITDA range now benefits from reduced expenses and ongoing performance improvements.

Additional News
No significant M&A, C-level changes, or dividend-related news was reported for Assertio Holdings in the three weeks following its August 11, 2025 earnings release. The sole external news item referenced was a general promotional message from RaiNews, an Italian news service, encouraging app downloads. The content was unrelated to Assertio’s financial results or operations.